Evidence map›Paper›PMID 35956763›Full record

ArticleMolecules (Basel, Switzerland)2022

Efficacy of Biologically Active Food Supplements for People with Atherosclerotic Vascular Changes.

Natalia Pleshkova, Boisjoni Tokhiriyon, Andrei Vekovtsev, Valeriy Mikhailovich Poznyakovsky, Valentina Lapina, Madina Atlaevna Takaeva, Vladimir Nikolaevich Sorokopudov, Elena Valeryevna Karanina

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 1 country.

Natalia PleshkovaDepartment of Economics and Management, Kemerovo State University, 650000 Kemerovo, Russia.
Boisjoni TokhiriyonDepartment of Management, Entrepreneurship and Engineering, Ural State University of Economics, 620144 Ekaterinburg, Russia.
Andrei VekovtsevDepartment of Production and Science, Scientific Production Association Artlife, 634034 Tomsk, Russia.
Valeriy Mikhailovich PoznyakovskyScientific and Educational Center for Applied Biotechnology and Nutrition, Kemerovo State Medical University, 650029 Kemerovo, Russia.
Valentina LapinaDepartment of Management, Entrepreneurship and Engineering, Ural State University of Economics, 620144 Ekaterinburg, Russia.
Madina Atlaevna TakaevaDepartment of Biology and Chemistry, Kadyrov Chechen State University, 364024 Grozny, Russia.
Vladimir Nikolaevich SorokopudovAll-Russian Scientific Research Institute of Medical and Aromatic Plants, 117216 Moscow, Russia.
Elena Valeryevna KaraninaDepartment of Economics and Finance, Vyatka State University, 610000 Kirov, Russia.
Ural State University of Economics · RUAll-Russian Scientific Research Institute of Medicinal and Aromatic Plants · RUChechen State University · RUKemerovo State Agricultural Institute · RUKemerovo State University · RUResearch Institute of Scientific Research and Production Association · RUVyatka State University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current paper deals with the development of a new biologically active food supplement (BAFS) aimed at treating atherosclerosis. Since atherosclerosis is considered to be a disease of aging, the composition of the supplement includes such essential minerals as magnesium and potassium, which are commonly used to prevent atherosclerosis, as well as vitamins C, E and the B-group vitamins in order to address the needs of the elderly. The authors outline the supplement-manufacturing technology and discuss the clinical trial undertaken by patients, aged about 60 years, with peripheral atherosclerosis. The research methodology focuses on studying the effectiveness of the developed supplement by assessing the influence of the active ingredients on treating metabolic disorders. To establish the efficacy of the supplement, blood tests, ultrasound and physical examinations were applied. The combination therapy resulted in improved metabolism and an overall better performance of the cardiovascular system; therefore, the BASF can be recommended as part of combination therapy to prevent and treat atherosclerotic and age-related changes in blood vessels.

Indexed as

AtherosclerosisDietary SupplementsAgedAscorbic AcidClinical Trials as TopicHumansMineralsVitaminsAscorbic AcidMineralsVitaminsBAFScombination therapyefficacyfunctional foodsperipheral atherosclerosis

Identifiers

PMID35956763
PMCPMC9370034
OpenAlexW4288081282

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.